EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Correlation analysis of serum amyloid A, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index with neoadjuvant therapy efficacy and prognosis in breast cancer

Yuanyuan Nong, Zhenzhen Zhou, Siyu Deng, Mengyu Liu, Xuefang Liang, Yonghua Jiang, Xinqing Ye, Aihua Tan

Frontiers in Oncology · 04.03.2026 · 16

DOI: 10.3389/fonc.2026.1695123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 04.03.2026. Verfasst von Yuanyuan Nong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast, Bone & Soft Tissue Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies have extensively explored the relationships between the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) with treatment efficacy and prognosis in breast cancer, though the conclusions have been inconsistent. Currently, research on serum amyloid A (SAA) in this context remains limited. This study aims to comprehensively evaluate the association of SAA, NLR, PLR, and SII with treatment response and prognosis in breast cancer, in order to explore which inflammatory marker may have the greatest prognosis value. Patients and methods We retrospectively analyzed 348 breast cancer patients treated between 2019 and 2021, including 113 patients who received neoadjuvant chemotherapy. Patients were stratified based on levels of inflammatory markers (SAA: 2.06 mg/L; NLR: 2.50; PLR: 162.89; SII: 650.66). The outcomes assessed included pathological complete response (pCR) and objective response rate (ORR) to neoadjuvant therapy, event-free survival (EFS), and overall survival (OS). Statistical analyses were conducted using Log-rank tests, Cox regression, and Logistic regression.

Results

Multivariate analysis identified high SAA as an independent correlate of reduced ORR (OR = 0.26, 95%CI: 0.08-0.80, p = 0.021). No inflammatory markers were found to have statistically significant correlates for pCR. For long-term prognosis, both elevated SAA and SII were independently associated with shorter OS (SAA: HR = 2.67, 95%CI: 1.14-6.26, p = 0.024; SII: HR = 2.65, 95%CI: 1.11-6.32, p = 0.028). Subgroup analysis revealed that among HER2+ patients, high SAA was independently correlated with both worse EFS (HR = 2.53, 95%CI: 1.06-6.07, p = 0.037) and OS (HR = 4.68, 95%CI: 1.11-19.70, p = 0.035). While, the independent associations of NLR and PLR with clinical outcomes were lost after adjusting for clinical confounders.

Conclusion

SAA appears to be independently associated with both ORR to neoadjuvant therapy and long-term survival outcomes in breast cancer patients, particularly those with HER2+ status, when compared to NLR, PLR, and SII.

Schlagwörter

Stichwörter der Autor:innen

breast cancerinflammatory biomarkersneoadjuvant therapyprognosisserum amyloid A

Autor:innen und Institutionen

  • Department of Breast, Bone & Soft Tissue Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
  • Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nann…
  • Pathology Department, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
  • School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
  • Laboratory of Breast Cancer Diagnosis and Treatment Research of Guangxi Department of Education, Nanning, Guangxi, China.

Zitieren

APA

Nong, Y., Zhou, Z., Deng, S., Liu, M., Liang, X., Jiang, Y., Ye, X., & Tan, A. (2026). Correlation analysis of serum amyloid A, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index with neoadjuvant therapy efficacy and prognosis in breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1695123

Vancouver

Nong Y, Zhou Z, Deng S, Liu M, Liang X, Jiang Y, et al. Correlation analysis of serum amyloid A, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index with neoadjuvant therapy efficacy and prognosis in breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1695123

BibTeX
@article{Nong2026,
  author = {Nong, Yuanyuan and Zhou, Zhenzhen and Deng, Siyu and Liu, Mengyu and Liang, Xuefang and Jiang, Yonghua and Ye, Xinqing and Tan, Aihua},
  title = {Correlation analysis of serum amyloid A, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index with neoadjuvant therapy efficacy and prognosis in breast cancer},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1695123}
}
Kostenlos starten →